Valneva SE Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (VALN). Impacted investors are advised to contact the firm now.

The investigation concerns whether Valneva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On May 7, 2025, and again on August 12, 2025, Valneva “confirmed its 2025 financial guidance.” Notably, the Company’s August 12, 2025 management update asserted that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) had lifted usage restrictions on IXCHIQ for older adults. However, just weeks later, on August 25, 2025, Valneva announced that the FDA had immediately suspended the U.S. license for IXCHIQ following reports of four serious adverse events mirroring chikungunya symptoms.

On this news, Valneva's stock price fell $2.58 per share, or approximately 22%, to close at $9.12 on August 25, 2025. This sharp decline resulted in significant losses for investors who purchased shares during this period.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.